Ring Christine 4
4 · Nurix Therapeutics, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) CLO Christine Ring Receives Equity Awards
What Happened
Christine Ring, Chief Legal Officer of Nurix Therapeutics, was granted equity awards on February 10, 2026: a stock option covering 93,750 shares and restricted stock units (RSUs) covering 42,875 shares. Both items are reported as derivative awards (transaction code A) with an acquisition price of $0.00 (i.e., they are non-cash grants, part of compensation rather than an open-market purchase).
Key Details
- Transaction date: 2026-02-10 (Form filed with accession 0001817199-26-000008 on same date).
- Awards: 93,750-share stock option (derivative) + 42,875 RSUs = 136,625 total awarded. Reported price: $0.00 (grant).
- Vesting for option (F1): vests 1/36 monthly beginning March 10, 2026, through February 9, 2029, subject to continued service.
- RSU details (F2–F4): each RSU equals a contingent right to one share; RSUs vest 1/12 quarterly over three years (first vesting July 30, 2026); RSUs do not expire but vest or are cancelled before vest dates; shares delivered after vesting.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing status: appears timely (same-day report).
Context
These are standard compensation grants (an option + RSUs) rather than purchases or sales; options and RSUs vest over time and convert to common stock only upon vesting (RSUs deliver shares; options require exercise). Such awards are routine for senior executives and reflect compensation, not an immediate market buy/sell signal.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-02-10+93,750→ 93,750 totalExercise: $16.45Exp: 2036-02-09→ Common Stock (93,750 underlying) - Award
Restricted Stock Units
[F2][F3][F4]2026-02-10+42,875→ 42,875 totalExercise: $0.00→ Common Stock (42,875 underlying)
Footnotes (4)
- [F1]The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F4]RSUs do not expire; they either vest or are canceled prior to the vest date.